Ruixia Investment

Founder Zheng Wei maintains direct control over the investment committee. The firm operates a lean team structure without publicly delegated sector heads or junior partners, making Zheng Wei the sole named decision-maker for capital deployment and portfolio monitoring.

Ruixia draws origination from China's university-affiliated research labs — particularly in computer vision and autonomous systems — and from state-sponsored science parks in Shanghai and Beijing. The firm's technical due-diligence reputation generates founder referrals within PhD-founder circles, bypassing the auction processes that define larger VC-led rounds.

Ruixia is explicitly not sector-agnostic. Its mandate filters for enterprises where the core competitive advantage is embedded in patented algorithms, semiconductor-level integration, or sensor-fusion architectures. Consumer internet, platform marketplaces, and asset-light service models are absent from the portfolio.

Ruixia typically reserves capital for pro-rata participation through Series B, particularly when follow-on rounds involve state industrial funds or SOE-affiliated co-investors. The firm does not publicly disclose its reserve ratio, but portfolio behavior suggests selective doubling-down on companies approaching regulatory licensing milestones.

The firm has never invested in e-commerce, social media, gaming, or content-platform businesses — categories that dominated Chinese venture returns between 2012 and 2020. Real estate, consumer credit, and clinical-stage biotech are also absent from the disclosed portfolio.

Portfolio companies like Megvii have appeared on US entity lists, but Ruixia's domestic LP base and renminbi denomination insulate the fund from dollar-denominated limited-partner pressure or CFIUS-style exit reviews. The firm's liquidity strategy relies on STAR Board, Hong Kong Stock Exchange, and strategic SOE acquisitions — venues that do not require US regulatory approval.

Ruixia concentrates on seed and Series A rounds, occasionally extending into Series B for portfolio companies reaching commercialization. The firm enters before revenue scale is proven, relying on technology audits and patent-filing velocity as underwriting signals, which distinguishes it from growth-stage renminbi funds that compete on revenue multiples.